Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchAndrographolideAndrographol.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Andrographolide for COVID-19: real-time meta analysis of 7 studies

@CovidAnalysis, April 2024, Version 8V8
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wanaratna (DB RCT) 86% 0.14 [0.01-2.61] progression 0/29 3/28 Improvement, RR [CI] Treatment Control Wanaratna (DB RCT) 40% 0.60 [0.33-1.09] viral+ 10/29 16/28 APFaVi Siripong.. (DB RCT) 50% 0.50 [0.05-5.39] hosp. 1/73 2/73 APFaVi Siripong.. (DB RCT) 50% 0.50 [0.05-5.39] hosp. 1/73 2/73 APFaVi Siripong.. (DB RCT) 86% 0.14 [0.01-2.72] oxygen 0/73 3/73 APFaVi Siripong.. (DB RCT) 49% 0.51 [0.05-5.47] progression 1/71 2/72 APFaVi Siripong.. (DB RCT) 37% 0.63 [0.31-1.30] no recov. 10/71 16/72 APFaVi Siripong.. (DB RCT) 4% 0.96 [0.81-1.15] no recov. 54/71 57/72 APFaVi Siripong.. (DB RCT) 33% 0.67 [0.34-1.30] no recov. 71 (n) 72 (n) APFaVi Siripong.. (DB RCT) -5% 1.05 [0.92-1.19] viral load 71 (n) 72 (n) APFaVi Siripong.. (DB RCT) -13% 1.13 [0.88-1.46] viral load 71 (n) 72 (n) Kanokkan.. (DB RCT) 51% 0.49 [0.15-1.58] progression 4/83 8/82 Kanokkan.. (DB RCT) 8% 0.92 [0.79-1.06] no recov. 64/83 69/82 Prasoppokak.. (RCT) 37% 0.63 [0.45-0.87] no recov. 43 (n) 39 (n) Prasoppokak.. (RCT) 18% 0.82 [0.39-1.73] no recov. 10/43 11/39 Prasoppokak.. (RCT) 46% 0.54 [0.32-0.91] no recov. 13/43 22/39 Prasoppokak.. (RCT) 55% 0.45 [0.04-4.81] no recov. 1/43 2/39 Prasoppokak.. (RCT) 40% 0.60 [0.11-3.43] no recov. 2/43 3/39 Prasoppokak.. (RCT) 30% 0.70 [0.35-1.41] no recov. 10/43 13/39 Prasoppokak.. (RCT) 42% 0.58 [0.25-1.34] no recov. 7/43 11/39 Prasoppokak.. (RCT) 45% 0.55 [0.23-1.32] no recov. 43 (n) 39 (n) Prasoppokak.. (RCT) 55% 0.45 [0.04-4.81] no recov. 1/43 2/39 Prasoppokak.. (RCT) 48% 0.52 [0.16-1.64] no recov. 4/43 7/39 Prasoppokak.. (RCT) 68% 0.32 [0.01-7.69] no recov. 0/43 1/39 Prasoppokak.. (RCT) 9% 0.91 [0.06-14.0] no recov. 1/43 1/39 Prasoppokak.. (RCT) 9% 0.91 [0.06-14.0] no recov. 1/43 1/39 Zhang (RCT) 92% 0.08 [0.01-0.76] severe case 0/65 6/65 Zhang (RCT) 48% 0.52 [0.32-0.85] no recov. 65 (n) 65 (n) Zhang (RCT) 40% 0.60 [0.34-1.05] no recov. 65 (n) 65 (n) Zhang (RCT) 61% 0.39 [0.23-0.68] no recov. 65 (n) 65 (n) Zhang (RCT) 53% 0.47 [0.32-0.68] viral+ 65 (n) 65 (n) Tanwettiyanont -26% 1.26 [0.74-2.17] progression 37/351 22/254 Prempree 19% 0.81 [0.48-1.38] viral+ 13/30 16/30 OT​1​ Andrographolide COVID-19 outcomes c19early.org April 2024 ​1​ OT: comparison with other treatment Favors andrographolide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit